Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

(2018) Robert J. Kreitman et al.   BLOOD

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

(2018) Robert J. Kreitman et al.   LEUKEMIA

Adverse Reactions to Biologic Therapy

(2017) Sheenal V. Patel et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

(2016) Michael R. Grever et al.   BLOOD

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

(2016) Dai Chihara et al.   BRITISH JOURNAL OF HAEMATOLOGY

2016 US lymphoid malignancy statistics by World Health Organization subtypes

(2016) Lauren R. Teras et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hairy cell leukaemia-variant: Disease features and treatment

(2015) Estella Matutes et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Immunoconjugates in the management of hairy cell leukemia

(2015) Robert J. Kreitman et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

(2015) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria

(2013) Haipeng Shao et al.   LEUKEMIA RESEARCH

CD22 ligation inhibits downstream B cell receptor signaling and Ca2+flux upon activation

(2012) N. Sieger et al.   ARTHRITIS AND RHEUMATISM

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

(2011) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

(2011) Monica Else et al.   LEUKEMIA & LYMPHOMA

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

(2009) Monica Else et al.   BRITISH JOURNAL OF HAEMATOLOGY

CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

(2009) R. F. Alderson et al.   CLINICAL CANCER RESEARCH

Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)

(2008) R. Zenhausern et al.   HAEMATOLOGICA

Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study

(2008) L Orsi et al.   OCCUPATIONAL AND ENVIRONMENTAL MEDICINE